Salarius Pharmaceuticals Inc. (SLRX)
Salarius Pharmaceuticals Statistics
Share Statistics
Salarius Pharmaceuticals has 2.13M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 2.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 6.11% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 106.3K |
| FTD / Avg. Volume | 38.7% |
Short Selling Information
The latest short interest is 112.93K, so 5.31% of the outstanding shares have been sold short.
| Short Interest | 112.93K |
| Short % of Shares Out | 5.31% |
| Short % of Float | 5.34% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.32 and the forward PE ratio is -0.04. Salarius Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.32 |
| Forward PE | -0.04 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 1.17 |
| P/FCF Ratio | -0.39 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Salarius Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.15.
| Current Ratio | 2.58 |
| Quick Ratio | 2.58 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | - |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.79M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -82.46% in the last 52 weeks. The beta is 0.6, so Salarius Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.6 |
| 52-Week Price Change | -82.46% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 42.08 |
| Average Volume (20 Days) | 274.69K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -5.58M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -5.79 |
Balance Sheet
The company has 2.43M in cash and 221.87K in debt, giving a net cash position of 2.21M.
| Cash & Cash Equivalents | 2.43M |
| Total Debt | 221.87K |
| Net Cash | 2.21M |
| Retained Earnings | -81.92M |
| Total Assets | 3.02M |
| Working Capital | 1.48M |
Cash Flow
In the last 12 months, operating cash flow was -4.53M and capital expenditures 0, giving a free cash flow of -4.53M.
| Operating Cash Flow | -4.53M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.53M |
| FCF Per Share | -4.7 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SLRX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -43 |
| Piotroski F-Score | 1 |